Comparative study of conventional dressing vs. topical heparin dressing in lower limb diabetic ulcers


  • N. M. Ashok Department of General Surgery, Trichy SRM Medical College Hospital and Research Centre, SRM Nagar, Irungalur, Thiruchirapalli, Tamil Nadu, India
  • Balamurugan C. Department of General Surgery, Trichy SRM Medical College Hospital and Research Centre, SRM Nagar, Irungalur, Thiruchirapalli, Tamil Nadu, India



Diabetic foot, Heparin dressing, Hospital stay


Background: Diabetic ulcers are a serious complication of diabetes that results in significant morbidity and mortality, especially lower limb diabetic ulcers are very difficult to treat due to the poor vascularity and brittle granulation tissue formed during the healing phase, so conventional dressings might not be that effective in treating the wound so this study aims to study the effectiveness of topical heparin over conventional dressings for lower limb diabetic foot ulcers

Methods: This is a prospective study done on 100 patients who presented to the surgical outpatient at Trichy SRM medical college hospital and research centre during the period December 2020 to July 2022 and diagnosed to have diabetic foot.

Results: On comparing the patients results of both groups with conventional and topical heparin dressings, the group with topical heparin dressing showed significant reduction in hospital stay and wound healed faster than the group with conventional dressing

Conclusions: Topical heparin dressing showed significant better results by reduction of hospital stay and faster healing of diabetic foot ulcers than wound treated with conventional dressing.


Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med. 2017; 376(24):2367-75.

Naves CCLM. The diabetic foot: a historical overview and gaps in current treatment. Adv wound care. 2016; 5(5):191-7.

Saliba MJ, Escamillo AR, Ramakrishnan KM, Jayaraman V, Zhao-fan X, Xu Lin C, et al. Heparin therapy in burns. Available at: https://www.townsend Accessed on 20 November 2021.

Gandhi NS, Mancera RL. Heparin/heparan sulphate-based drugs. Drug Discov Today. 2010;15:1058-69.

Thachil J. Clinical Differentiation of Anticoagulant and non-Anticoagulant properties of heparin. J Thromb Haemost. 2020;18:2424-5.

Fan SQ, Qin LY, Cai JL, Zhu GY, Bin X, Yan HS. Effect of heparin on production of basic fibroblast growth factor and transforming growth factor-beta1 by human normal skin and hyperplastic scar fibroblasts. J Burn Care Res. 2007;28:734-41.

Azizkhan RG, Azizkhan JC, Zetter BR, Folkman J. Mast cell heparin stimulates migration of capillary endothelial cells in vitro. J Exp Med. 1980;152(4): 931-44.

Folkman J., Shing Y. Control of angiogenesis by heparin and other sulphated polysaccharides. Adv Exp Med Biol. 1992;313:355-64.

Zapat-Sirvant RL, Hansbrough JF, Greenleaf GE. Reduction of bacterial translocation and intestinal structure alterations by heparin in a murine burn injury model. J Trauma. 1994;36:1-6.






Original Research Articles